原発性胆汁性胆管炎の世界市場レポート 2025年

原発性胆汁性胆管炎市場規模は、今後数年間で力強い成長が見込まれます。2029年には16億米ドルに成長し、CAGRは9.9%となります。予測期間の成長は、バイオマーカー研究の拡大、希少疾患管理における世界の取り組み、臨床試験における協力体制の強化、患者中心のヘルスケアアプローチ、肝移植需要の高まりなどに起因すると考えられます。予測期間における主な動向としては、バイオマーカー研究の進展、非侵襲的診断技術の重視の高まり、免疫調節療法に関する研究の重点化、人工知能（AI）の統合、臨床試験における患者報告アウトカム、患者管理のための遠隔医療、併用療法の重点化、線維症を標的とした新たな治療法などが挙げられます。

予想される喫煙の増加は、今後数年間の原発性胆汁性胆管炎市場の拡大を牽引する構えです。喫煙は、タバコやその他の物質の燃焼によって発生する煙を吸ったり吐いたりすることです。喫煙は、PBCを含む肝疾患の危険因子として認識されており、喫煙率の上昇は、肝臓関連の問題で診察を受ける人の増加をもたらす可能性があります。一例として、2023年7月、カナダ統計局は、2023年6月と比較して2.2％のたばこ生産量の増加を報告し、それに対応してたばこ販売量も2.6％増加し、6月は5月と比較して14億本に達しました。その結果、喫煙の増加は原発性胆汁性胆管炎市場の成長を促進すると予想されます。

肝臓がんの増加は、今後の原発性胆汁性胆管炎市場の成長を促進すると予想されます。肝臓がんは、肝細胞がんとしても知られ、肝臓細胞から始まるがんの一種です。原発性胆汁性胆管炎は、胆管がんや肝細胞がんなど、さまざまな悪性腫瘍のリスクを高めるため、肝臓がんにおいて重要な役割を果たしています。この疾患の有病率の増加と潜在的な合併症が、原発性胆汁性胆管炎市場の拡大に寄与しています。例えば、米国の代表的な専門機関である米国がん協会では、2024年1月に国内で新たに肝がんに罹患する患者数を約41,630人と予測しており、その内訳は男性が28,000人、女性が13,630人となっています。さらに、約29,840人（男性19,120人、女性10,720人）がこの病気で死亡すると予想されています。その結果、肝臓がん患者の増加が原発性胆汁性胆管炎市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界原発性胆汁性胆管炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の原発性胆汁性胆管炎市場：成長率分析
• 世界の原発性胆汁性胆管炎市場の実績：規模と成長, 2019-2024
• 世界の原発性胆汁性胆管炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界原発性胆汁性胆管炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の原発性胆汁性胆管炎市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• 肝臓移植
• 世界の原発性胆汁性胆管炎市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像検査
• 磁気共鳴エラストグラフィー（MRE）
• 磁気共鳴胆道膵管造影検査（MRCP）
• 超音波
• フィブロスキャン
• 血液検査
• コレステロール検査
• 抗体検査
• 肝臓検査
• その他の診断
• 世界の原発性胆汁性胆管炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の原発性胆汁性胆管炎市場、薬物の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウルソデオキシコール酸（UDCA）
• オベチコール酸（OCA）
• フィブラート
• 免疫抑制薬
• その他の標的療法
• 世界の原発性胆汁性胆管炎市場、肝移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 同所性肝移植（OLT）
• 生体肝移植
• 肝移植のための肝胆道外科手術

第7章 地域別・国別分析

• 世界の原発性胆汁性胆管炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の原発性胆汁性胆管炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性胆汁性胆管炎市場：競合情勢
• 原発性胆汁性胆管炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc
• Arrowhead Pharmaceuticals Inc.
• CureVac N.V.
• Sangamo Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 原発性胆汁性胆管炎市場2029：新たな機会を提供する国
• 原発性胆汁性胆管炎市場2029：新たな機会を提供するセグメント
• 原発性胆汁性胆管炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC. UDCA helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through various imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, as well as blood tests including cholesterol tests, antibody tests, and liver function tests. These diagnostic methods are employed by end-users such as specialty clinics, homecare services, and other healthcare facilities.

The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary biliary cholangitis market size has grown rapidly in recent years. It will grow from $0.98 billion in 2024 to $1.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increased disease awareness, rising global healthcare expenditure, strategic collaborations in the healthcare sector, focus on patient advocacy, government initiatives for liver health.

The primary biliary cholangitis market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of biomarker research, global efforts in rare disease management, increased collaboration in clinical trials, patient-centric healthcare approaches, rising demand for liver transplants. Major trends in the forecast period include advancements in biomarker research, growing emphasis on non-invasive diagnostic techniques, research focus on immunomodulatory therapies, integration of artificial intelligence (ai), patient-reported outcomes in clinical trials, telemedicine for patient management, focus on combination therapies, emerging therapies targeting fibrosis.

The anticipated rise in smoking is poised to drive the expansion of the primary biliary cholangitis market in the coming years. Smoking involves the inhalation and exhalation of smoke generated by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and elevated smoking rates may result in an increased number of individuals seeking medical attention for liver-related issues. As an illustration, in July 2023, Statistics Canada reported a 2.2% increase in cigarette production compared to June 2023, with a corresponding 2.6% rise in cigarette sales, reaching 1.4 billion units in June compared to May. Consequently, the upswing in smoking is expected to propel the primary biliary cholangitis market's growth.

The rise in liver cancer is expected to drive the growth of the primary biliary cholangitis market in the future. Liver cancer, also known as hepatocellular carcinoma, is a type of cancer that begins in the liver cells. Primary biliary cholangitis plays a significant role in liver cancer due to the increased risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The growing prevalence of this disease and its potential complications are contributing to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a leading professional organization in the U.S., projected approximately 41,630 new cases of liver cancer in the country, with 28,000 cases in men and 13,630 in women. Additionally, about 29,840 individuals (19,120 men and 10,720 women) are expected to die from the disease. As a result, the increase in liver cancer cases is driving the growth of the primary biliary cholangitis market.

Major companies operating in the primary biliary cholangitis market are directing their efforts towards the development of innovative and specialized treatments. This includes the creation of orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), aiming to secure market exclusivity. The combination of OCA and bezafibrate, with an orphan drug designation, seeks to provide a more comprehensive and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate as a potential treatment for PBC, a progressive liver disease, with OCA already approved for PBC in the US.

In March 2023, Ipsen SA, a France-based pharmaceutical company, completed the acquisition of Albireo Pharma, Inc. for an undisclosed amount. This strategic move by Ipsen aims to broaden its rare disease portfolio by incorporating novel pipeline prospects, promising therapies for rare cholestatic liver diseases in both children and adults, and leveraging strong scientific and commercial capabilities. Albireo Pharma Inc., a US-based biopharmaceutical company, is actively developing A3907 therapy for primary biliary cholangitis (PBC), contributing to Ipsen's expansion in the rare disease segment.

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary biliary cholangitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Drugs; Liver Transplantation
• 2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
• 3) By End-Users: Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies
• 2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Biliary Cholangitis Market Characteristics

3. Primary Biliary Cholangitis Market Trends And Strategies

4. Primary Biliary Cholangitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Biliary Cholangitis Market Growth Rate Analysis
• 5.4. Global Primary Biliary Cholangitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Biliary Cholangitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Biliary Cholangitis Total Addressable Market (TAM)

6. Primary Biliary Cholangitis Market Segmentation

• 6.1. Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Liver Transplantation
• 6.2. Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Magnetic Resonance Elastography (MRE)
• Magnetic Resonance Cholangiopancreatography (MRCP)
• Ultrasound
• Fibroscan
• Blood Tests
• Cholesterol Test
• Antibody Tests
• Liver Tests
• Other Diagnoses
• 6.3. Global Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specialty Clinics
• Homecare
• Other End-Users
• 6.4. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ursodeoxycholic Acid (UDCA)
• Obeticholic Acid (OCA)
• Fibrates
• Immunosuppressive Drugs
• Other Targeted Therapies
• 6.5. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Liver Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Orthotopic Liver Transplantation (OLT)
• Living Donor Liver Transplantation
• Hepatobiliary Surgery For Liver Transplant

7. Primary Biliary Cholangitis Market Regional And Country Analysis

• 7.1. Global Primary Biliary Cholangitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Biliary Cholangitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Market

• 8.1. Asia-Pacific Primary Biliary Cholangitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Biliary Cholangitis Market

• 9.1. China Primary Biliary Cholangitis Market Overview
• 9.2. China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Biliary Cholangitis Market

• 10.1. India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Biliary Cholangitis Market

• 11.1. Japan Primary Biliary Cholangitis Market Overview
• 11.2. Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Biliary Cholangitis Market

• 12.1. Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Biliary Cholangitis Market

• 13.1. Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Biliary Cholangitis Market

• 14.1. South Korea Primary Biliary Cholangitis Market Overview
• 14.2. South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Biliary Cholangitis Market

• 15.1. Western Europe Primary Biliary Cholangitis Market Overview
• 15.2. Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Biliary Cholangitis Market

• 16.1. UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Biliary Cholangitis Market

• 17.1. Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Biliary Cholangitis Market

• 18.1. France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Biliary Cholangitis Market

• 19.1. Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Biliary Cholangitis Market

• 20.1. Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Market

• 21.1. Eastern Europe Primary Biliary Cholangitis Market Overview
• 21.2. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Biliary Cholangitis Market

• 22.1. Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Biliary Cholangitis Market

• 23.1. North America Primary Biliary Cholangitis Market Overview
• 23.2. North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Biliary Cholangitis Market

• 24.1. USA Primary Biliary Cholangitis Market Overview
• 24.2. USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Biliary Cholangitis Market

• 25.1. Canada Primary Biliary Cholangitis Market Overview
• 25.2. Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Biliary Cholangitis Market

• 26.1. South America Primary Biliary Cholangitis Market Overview
• 26.2. South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Biliary Cholangitis Market

• 27.1. Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Biliary Cholangitis Market

• 28.1. Middle East Primary Biliary Cholangitis Market Overview
• 28.2. Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Biliary Cholangitis Market

• 29.1. Africa Primary Biliary Cholangitis Market Overview
• 29.2. Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Biliary Cholangitis Market Competitive Landscape And Company Profiles

• 30.1. Primary Biliary Cholangitis Market Competitive Landscape
• 30.2. Primary Biliary Cholangitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Primary Biliary Cholangitis Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH.
• 31.6. Gilead Sciences Inc.
• 31.7. Vertex Pharmaceuticals
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Ionis Pharmaceuticals Inc.
• 31.12. Intercept Pharmaceuticals Inc
• 31.13. Arrowhead Pharmaceuticals Inc.
• 31.14. CureVac N.V.
• 31.15. Sangamo Therapeutics Inc.

32. Global Primary Biliary Cholangitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Market

34. Recent Developments In The Primary Biliary Cholangitis Market

35. Primary Biliary Cholangitis Market High Potential Countries, Segments and Strategies

• 35.1 Primary Biliary Cholangitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Biliary Cholangitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Biliary Cholangitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer